In particular, there is increasing recognition that HER2-positive BC is characterized by poor clinical prognostic features, which translate into aggressive tumor behavior, and importantly by experimental and clinical resistance to endocrine therapy [36]. The gene discussed is ERBB2; the disease is neoplasm.